PATENT CLAIM ANALYSIS

Application Number: 16039781
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "275000"]

Abstract:
The present invention relates to a pharmaceutical composition containing a G protein coupled receptor 119 (GPR119) ligand as an effective ingredient for preventing or treating non-alcoholic steatohepatitis. More particularly, it was confirmed that the GPR119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the GPR119 ligand can be useful to treat non-alcoholic steatohepatitis.

Claim (Index 7):
The pharmaceutical composition according to  claim 1 , wherein the GPR119 ligand inhibits expression of acetyl CoA carboxylase (ACC).

Metadata:
- Claim Count in Document: 29.0
- Percentile: 95.0
- Lexical Diversity: 1.3913
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15355376', '15759588', '13057401', '15312663', '15337208']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7706335323590401
- 35 USC 102 Novelty (BERT): 0.5279325272424713
- Combined Prediction Score: 0.7463634318473833
- Mean Citation Score: 246.050886
- Max Citation Score: 339.23883
- Similarity Product: 248.95059815384568

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test